Gracell Biotechnologies to Participate in Four Upcoming Investor Conferences
Nov 02, 2021 
SUZHOU, China and PALO ALTO, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it will participate in the following upcoming conferences:
Goldman Sachs Asia Pacific Healthcare Forum 2021
One-on-one and small group meetings (virtual): November 15-17, 2021
For more information, please contact your Goldman Sachs representative.
8th BioCentury-BayHelix China Healthcare Summit
In-person one-on-one and small group meetings (Shanghai, China): November 17, 2021
Panel - China Biotech CEO Blue Ribbon Roundtable: November 17, 2021, 14:30-15:15pm CST
For more information, please contact your Biocentury representative.
Jefferies London Healthcare Conference
One-on-one and small group meetings (virtual): November 18-19, 2021
Fireside Chat: available on-demand beginning on Thursday, November 18, 3:00am ET
Webcast link: https://ir.gracellbio.com/news-events/events-and-presentations
The replay of the fireside chat can be accessed through the “News and Events” section of the Gracell Investor website.
For more information, please contact your Jefferies representative.
20th Morgan Stanley Annual Asia Pacific Summit
One-on-one and small group meetings (virtual): November 18-19, 2021
For more information, please contact your Morgan Stanley representative.
About Gracell
Gracell Biotechnologies Inc. ("Gracell") is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal production quality, high therapy cost and lack of effective CAR-T therapies for solid tumors. For more information on Gracell, please visit www.gracellbio.com
Follow @GracellBio on LinkedIn
Media contact
Marvin Tang
Investor contact
Gracie Tong